Epoetin and cardiac function:An echocardiographic analysis in patients with heart failure.

Improved cardiac function following the acute intravenous administration of epoetin alpha in patients with heart failure. An echocardiographic, placebo controlled study.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12607000042448

Acronym

Nil

Enrollment

Registered

2007-01-12

Start date

2006-08-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

A preliminary study to evaluate the acute effect (2 hours) of a commonly used treatment for anaemia in renal failure on cardiac function (strength) in patients with cardiac failure.The potential benefits are based on a recent study(unpublished) that observed an effect of intravenous epoetin alpha on heart and large blood vessel (aorta) function.Patient and echocardiographer blinded to treatment/placebo order.

Interventions

Intravenous administration of epoetin alpha(10,000U)and subsequent echocardiography(45 & 120 min later)-then after a 135 min washout period,a small volume ( 1 ml)normal saline ( placebo) is given followed by repeat echocardiography 45 & 120 min later.Trial drug and placebo given only once.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Any form of cadiac failure.

Exclusion criteria

Allergy to epoetin alpha.

Outcome results